# In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on CSL, with a price target of A$166.00.

*business · news · 2026-05-12 · Markets Insider*

## Key points

- Morgan Stanley's David Bailey maintained a Buy rating on CSL with a A$166.00 price target.
- Morgans’s Derek Jellinek also issued a Buy rating for CSL on the same day.
- Citi downgraded CSL to a Hold rating yesterday, contrasting recent positive ratings.
- CSL's latest quarterly profit dropped to A$408.37 million from last year's A$2.01 billion.

**Companies:** CSL, Morgan Stanley, Citi, Telix Pharmaceuticals, Ramsay Health Care, Cochlear
**Countries:** Australia, United States

[Read the full story on Markets Insider](https://markets.businessinsider.com/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-csl-cmxhf-1036141671)

---

Canonical: https://newsio.io/n/42926e89-ce19-4785-ae1a-bb3c3a4bdd03/in-a-report-released-today-david-bailey-from-morgan-stanley-maintained-a-buy-rat
Summarized by Newsio from Markets Insider. https://newsio.io/how-it-works